Last reviewed · How we verify

NCT03931330

Does Improving Vagal Tone Increase Mitochondrial Bioenergetics

Completed NA Results posted Last updated 21 June 2021
What this trial tests

NA trial testing Percutaneous neurostimulation in Functional Gastrointestinal Disorders in 8 participants. Completed in 24 September 2019.

Timeline
6 February 2019
Primary endpoint
24 September 2019
24 September 2019

Quick facts

Lead sponsorMedical College of Wisconsin
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment8
Start date6 February 2019
Primary completion24 September 2019
Estimated completion24 September 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medical College of Wisconsin

Who can join

Adults 12 to 18, any sex, with Functional Gastrointestinal Disorders or Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

To Measure Different Mitochondrial Bioenergetic Markers, Including Basal Respiratory Capacity Primary · Baseline, at follow-up visit 4 (Week 4) and at follow up visit 5 (Week 8 or 12)

Blood draw will be tested for mitochondrial function, including basal respiratory capacity, ATP production and spare respiration and to detect changes in protein which can be an indicator for inflammation. Basal Respiratory Capacity (pmol/min) is better when value is higher.

Week 1
GroupValue95% CI
Only Active Devise, Open Label221.85± 195.35
Week 4
GroupValue95% CI
Only Active Devise, Open Label151.14± 101.97
Week 8
GroupValue95% CI
Only Active Devise, Open Label139.20± 120.12
To Measure Heart Rate Variability Secondary · At date of baseline assessment (beginning of therapy). Also assessed at follow-up visit 4 (Week 4) and 5 (Week 8 or 12)

EKG tracing will be used to analyze Heart Rate Variability as an indirect measure of vagal nerve output and central autonomic control.

Week 1
GroupValue95% CI
Only Active Devise, Open Label100.31± 17.31
Week 4
GroupValue95% CI
Only Active Devise, Open Label97.27± 21.69
Week 8
GroupValue95% CI
Only Active Devise, Open Label93.86± 15.63
Total
GroupValue95% CI
Only Active Devise, Open Label97.35± 18.17
To Measure Functional Disability Inventory Secondary · At date of baseline assessment (beginning of therapy). Also assessed at follow-up visit 4 (Week 4) and visit 5 (8 or 12)

The Functional Disability Inventory (FDI) questionnaire will be used to assess change in symptoms. Participants will rank physical trouble or difficulty completing 15 different daily activities (Eating regular meals, Being at school all day, Walking up stairs, etc.) on a scale of 0-4. Scale:0-No trouble 1. A little trouble 2. Some Trouble 3. A lot of Trouble 4. Impossible Higher scores (4) indicate more difficulty functioning due to physical health. The total score ranges from 0 to 60 among 15 questions. The individual score for all 15 questions are added together for the total score. If al

Week 1
GroupValue95% CI
Only Active Devise, Open Label26.53± 14.04
Week 4
GroupValue95% CI
Only Active Devise, Open Label24.58± 15.25
Week 8
GroupValue95% CI
Only Active Devise, Open Label22.70± 17.47
Total
GroupValue95% CI
Only Active Devise, Open Label24.74± 14.60

Sponsor's own description

This study evaluates the effect of auricular neurostimulation on mitochondrial bioenergetics and inflammation through vagal nerve modulation via non-invasive percutaneous electrical nerve field stimulator in children with functional gastrointestinal disorders.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients.
    Czura CJ, Bikson M, Charvet L, Chen JDZ, et al · · 2022 · cited 13× · PMID 35911909 · DOI 10.3389/fneur.2022.897124

Verify or expand the search:

Other trials of Percutaneous neurostimulation

Trials testing the same drug.

Other recruiting trials for Functional Gastrointestinal Disorders

Currently open trials in the same condition.

Other Medical College of Wisconsin trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03931330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing